Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Science. 2011 Oct 28;334(6055):525-8. doi: 10.1126/science.1209909.

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Author information

  • 1Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.

Abstract

Germline mutations of the breast cancer 1 (BRCA1) gene are a major cause of familial breast and ovarian cancer. The BRCA1 protein displays E3 ubiquitin ligase activity, and this enzymatic function is thought to be required for tumor suppression. To test this hypothesis, we generated mice that express an enzymatically defective Brca1. We found that this mutant Brca1 prevents tumor formation to the same degree as does wild-type Brca1 in three different genetically engineered mouse (GEM) models of cancer. In contrast, a mutation that ablates phosphoprotein recognition by the BRCA C terminus (BRCT) domains of BRCA1 elicits tumors in each of the three GEM models. Thus, BRCT phosphoprotein recognition, but not the E3 ligase activity, is required for BRCA1 tumor suppression.

Comment in

PMID:
22034435
[PubMed - indexed for MEDLINE]
PMCID:
PMC3904783
Free PMC Article

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk